MNTA: OK, but 1. Fragmin is wholly-owned by MNTA. 2. The 2 undisclosed protein FoB's garner such a huge potential market that any royalty arrangement should be quite substantial for MNTA. Evidence the slide below regarding the M356 Copaxone arrangement:
>MNTA – don't think fragmin is going anywhere, the upside doesn't justify the investment since fragmin is only a modest seller.<
If MNTA eventually gets approval for generic Lovenox, it ought to be a piece of cake to submit an ANDA for Fragmin and get it approved because the two drugs are so similar.
Generic Fragmin is clearly not a big-ticket item, but I would argue that it represents almost-free money. Hence, “reprioritized” does not necessarily mean dead, IMO.
Market Data 
Markets 
AI
